Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)
The main part of this Phase 2a study will consist of 3 study periods: a Screening Period, a Treatment Period and a Safety Follow-up Period. All participants who complete the open-label Treatment Period will have the opportunity to continue their treatment in an optional 26-week Long-term Extension study after completing the Week 52 assessments.
Age
18–85
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Has signs/symptoms of moderately to severely active UC for at least 3 months prior to Screening
Has evidence of UC extending at least 15 cm from the anal verge
Is bio-naïve or had an inadequate response, loss of response, or intolerance to other UC drugs
Agrees to abide by the study guidelines and requirements
Capable of giving signed informed consent
You may not be if
Diagnosed with indeterminate colitis, microscopic colitis, ischemic colitis, radiation colitis, or Crohn's disease or has clinical findings suggestive of Crohn's disease
Has positive findings on a subjective neurological screening questionnaire
Has a concurrent, clinically significant, serious, unstable comorbidity
Primary non-responder to vedolizumab or other integrin inhibitors
Participation in any other interventional study or received any investigational therapy within 30 days
Previous exposure to MORF-057 and/or a known hypersensitivity to drugs with a similar mechanism to MORF-057
Unable to attend study visits or comply with study procedures
